GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    SARS‐CoV‐2 respiratory viral loads and association with clinical and biological features
    Wiley ; 2021
    In:  Journal of Medical Virology Vol. 93, No. 3 ( 2021-03), p. 1761-1765
    Details
    In: Journal of Medical Virology, Wiley, Vol. 93, No. 3 ( 2021-03), p. 1761-1765
    Abstract: To determine the distribution of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) respiratory viral loads (VL) during the acute phase of infection and their correlation with clinical presentation and inflammation‐related biomarkers. Nasopharyngeal swabs from 453 adult SARS‐CoV‐2‐infected patients from the Department of Infectious Diseases, Besançon, France, were collected at the time of admission or consultation for reverse transcriptase polymerase chain reaction (RT‐PCR) analysis. Clinical information and concentrations of biological parameters (C‐reactive protein [CRP], fibrinogen, lactate dehydrogenase [LDH] , prealbumin) were noticed. Mean respiratory VL homogeneously decreased from 7.2 log 10 copies/ml (95% confidence interval [CI]: 6.6–7.8) on the first day of symptoms until 4.6 log 10 copies/ml (95% CI: 3.8–5.4) at day 10 (slope = −0.24; R 2  = .95). VL were poorly correlated with COVID‐19 symptoms and outcome, excepted for dyspnea and anosmia, which were significantly associated with lower VL ( p   〈  .05). CRP, fibrinogen, and LDH concentrations significantly increased over the first 10 days (median CRP concentrations from 36.8 mg/L at days 0–1 to 99.5 mg/L at days 8–10; p   〈  .01), whereas prealbumin concentrations tended to decrease. Since SARS‐CoV‐2 respiratory VL regularly decrease in the acute phase of infection, determining the level of VL may help predicting the onset of virus shedding in a specific patient. However, the role of SARS‐CoV‐2 VL as a biomarker of severity is limited.
    Type of Medium: Online Resource
    ISSN: 0146-6615 , 1096-9071
    URL: Issue
    URL: Article
    DOI: 10.1002/jmv.v93.3
    DOI: 10.1002/jmv.26489
    RVK:
    XA 10000
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 752392-0
    detail.hit.zdb_id: 1475090-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Olfactory dysfunction in COVID‐19, new insights from a cohort of 353 patients: The ANOSVID study
    Wiley ; 2022
    In:  Journal of Medical Virology Vol. 94, No. 10 ( 2022-10), p. 4762-4775
    Details
    In: Journal of Medical Virology, Wiley, Vol. 94, No. 10 ( 2022-10), p. 4762-4775
    Abstract: Olfactory disorders (OD) pathogenesis, underlying conditions, and prognostic in coronavirus disease 2019 (COVID‐19) remain partially described. ANOSVID is a retrospective study in Nord Franche‐Comté Hospital (France) that included COVID‐19 patients from March 1 2020 to May 31 2020. The aim was to compare COVID‐19 patients with OD (OD group) and patients without OD (no‐OD group). A second analysis compared patients with anosmia (high OD group) and patients with hyposmia or no OD (low or no‐OD group). The OD group presented less cardiovascular and other respiratory diseases compared to the no‐OD group (odds ratio [OR] = 0.536 [0.293–0.981] , p  = 0.041 and OR = 0.222 [0.056–0.874], p  = 0.037 respectively). Moreover, history of malignancy was less present in the high OD group compared with the low or no‐OD group (OR = 0.170 [0.064–0.455], p   〈  0.001). The main associated symptoms (OR  〉  5) with OD were loss of taste (OR = 24.059 [13.474–42.959], p  = 0.000) and cacosmia (OR = 5.821 [2.246–15.085], p   〈  0.001). Most of all ORs decreased in the second analysis, especially for general, digestive, and ENT symptoms. Only two ORs increased: headache (OR = 2.697 [1.746–4.167] , p   〈  0.001) and facial pain (OR = 2.901 [1.441–5.842], p  = 0.002). The high OD group had a higher creatinine clearance CKD than the low or no‐OD group (89.0 ± 21.1 vs. 81.0 ± 20.5, p  = 0.040). No significant difference was found concerning the virological, radiological, and severity criteria. OD patients seem to have less comorbidity, especially better cardiovascular and renal function. Associated symptoms with OD were mostly neurological symptoms. We did not find a significant relationship between OD and less severity in COVID‐19 possibly due to methodological bias.
    Type of Medium: Online Resource
    ISSN: 0146-6615 , 1096-9071
    URL: Issue
    URL: Article
    DOI: 10.1002/jmv.v94.10
    DOI: 10.1002/jmv.27918
    RVK:
    XA 10000
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 752392-0
    detail.hit.zdb_id: 1475090-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    Chronic use of renin‐angiotensin‐aldosterone system blockers and mortality in COVID‐19: A multicenter prospective cohort and literature review
    Wiley ; 2021
    In:  Fundamental & Clinical Pharmacology Vol. 35, No. 6 ( 2021-12), p. 1141-1158
    Details
    In: Fundamental & Clinical Pharmacology, Wiley, Vol. 35, No. 6 ( 2021-12), p. 1141-1158
    Abstract: The role of renin‐angiotensin‐aldosterone system (RAAS) blockers on the course of coronavirus disease 2019 (COVID‐19) is debated. We assessed the association between chronic use of RAAS blockers and mortality among inpatients with COVID‐19 and explored reasons for discrepancies in the literature. Methods and results We included adult hypertensive patients from a prospective nationwide cohort of 3512 inpatients with COVID‐19 up to June 30, 2020. Cox proportional hazard models with various adjustment or propensity weighting methods were used to estimate the hazard ratios (HR) of 30‐day mortality for chronic users versus non‐users of RAAS blockers. We analyzed data of 1160 hypertensive patients: 719 (62%) were male and 777 (67%) were older than 65 years. The main comorbidities were diabetes ( n  = 416, 36%), chronic cardiac disease ( n  = 401, 35%), and obesity ( n  = 340, 29%); 705 (61%) received oxygen therapy. We recorded 135 (11.6%) deaths within 30 days of diagnosis. We found no association between chronic use of RAAS blockers and mortality (unadjusted HR = 1.13, 95% CI [0.8–1.6]; propensity inverse probability treatment weighted HR = 1.09 [0.86‐1.39] ; propensity standardized mortality ratio weighted HR = 1.08 [0.79–1.47]). Our comprehensive review of previous studies highlighted that significant associations were mostly found in unrestricted populations with inappropriate adjustment, or with biased in‐hospital exposure measurement. Conclusion Our results do not support previous concerns regarding these drugs, nor a potential protective effect as reported in previous poorly designed studies and meta‐analyses. RAAS blockers should not be discontinued during the pandemic, while in‐hospital management of these drugs will be clarified by randomized trials. NCT04262921.
    Type of Medium: Online Resource
    ISSN: 0767-3981 , 1472-8206
    URL: Issue
    URL: Article
    DOI: 10.1111/fcp.v35.6
    DOI: 10.1111/fcp.12683
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2006242-4
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Characteristics, management, and outcomes of patients with left‐sided infective endocarditis complicated by heart failure: a substudy of the ESC‐EORP EURO‐ENDO (European infective endocarditis) registry
    Wiley ; 2022
    In:  European Journal of Heart Failure Vol. 24, No. 7 ( 2022-07), p. 1253-1265
    Details
    In: European Journal of Heart Failure, Wiley, Vol. 24, No. 7 ( 2022-07), p. 1253-1265
    Abstract: To evaluate the current management and survival of patients with left‐sided infective endocarditis (IE) complicated by congestive heart failure (CHF) in the ESC‐EORP European Endocarditis (EURO‐ENDO) registry. Methods and results Among the 3116 patients enrolled in this prospective registry, 2449 (mean age: 60 years, 69% male) with left‐sided (native or prosthetic) IE were included in this study. Patients with CHF ( n  = 698, 28.5%) were older, with more comorbidity and more severe valvular damage (mitro‐aortic involvement, vegetations 〉 10 mm and severe regurgitation/new prosthesis dehiscence) than those without CHF (all p  ≤ 0.019). Patients with CHF experienced higher 30‐day and 1‐year mortality than those without (20.5% vs. 9.0% and 36.1% vs. 19.3%, respectively) and CHF remained strongly associated with 30‐day (odds ratio[OR] 2.37, 95% confidence interval [CI] [1.73–3.24; p   〈  0.001) and 1‐year mortality (hazard ratio [HR] 1.69, 95% CI 1.39–2.05; p   〈  0.001) after adjustment for established outcome predictors, including early surgery, or after propensity matching for age, sex, and comorbidity ( n  = 618 [88.5%] for each group, both p   〈  0.001). Early surgery, performed on 49% of these patients with IE complicated by CHF, remained associated with a substantial reduction in 30‐day mortality following multivariable analysis, after adjustment for age, sex, Charlson comorbidity index, cerebrovascular accident, Staphylococcus aureus IE, streptococcal IE, uncontrolled infection, vegetation size 〉 10 mm, severe valvular regurgitation and/or new prosthetic dehiscence, perivalvular complication, and prosthetic IE (OR 0.22, 95% CI 0.12–0.38; p   〈  0.001) and in 1‐year mortality (HR 0.29, 95% CI 0.20–0.41; p   〈  0.001). Conclusion Congestive heart failure is common in left‐sided IE and is associated with older age, greater comorbidity, more advanced lesions, and markedly higher 30‐day and 1‐year mortality. Early surgery is strongly associated with lower mortality but is performed on only approximately half of patients with CHF, mainly because of a surgical risk considered prohibitive.
    Type of Medium: Online Resource
    ISSN: 1388-9842 , 1879-0844
    URL: Issue
    URL: Article
    DOI: 10.1002/ejhf.v24.7
    DOI: 10.1002/ejhf.2525
    Language: English
    Publisher: Wiley
    Publication Date: 2022
    detail.hit.zdb_id: 1500332-2
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    A survey investigating the current practice of French health professionals regarding infection risk after monkey bites
    Wiley ; 2020
    In:  Zoonoses and Public Health Vol. 67, No. 2 ( 2020-03), p. 193-197
    Details
    In: Zoonoses and Public Health, Wiley, Vol. 67, No. 2 ( 2020-03), p. 193-197
    Abstract: International tourism is steadily increasing, with 15% of travellers reporting health problems when they come back. Animal bites represent 2% of consulting causes, of which 20% are due to monkey bites. The Monkey B virus ( Macacine alphaherpesvirus 1) is an alphaherpesvirus ( Herpesviridae , genus Simplexvirus ) enzootic in macaques (Genus Macaca ). Zoonotic infections with the Monkey B virus following exposure to macaques are exceptionally rare, but can cause fatal encephalomyelitis in humans. An observational survey was undertaken in 2018 to assess the practice of French health professionals regarding infection risk after monkey bites. French health professionals practicing in vaccination and rabies centres were specifically targeted for this study. Standardized questionnaires were sent by email to a sample of French health professionals. They were asked to participate on a voluntary and anonymous basis. The questionnaires requested epidemiological details and included multiple‐choice questions about the infection management of monkey bites. The response rate was 33.5%. The frequency of monkey bites in 2017 was variable with a minority of centres managing more than 6 per year (12%), 46% managing 1–5 monkey bites and 42% none. Most of the monkey bites were described as occurring in South Asia at tourist sites, on naked upper limbs, shortly after the travellers arrived at their destination. Tetanus status verification, rabies post‐exposure prophylaxis and antibiotic therapy were said to be prescribed in most cases. Knowledge about the Monkey B virus was reported as scarce for 38% of the participants. The number of monkey bites managed per year per centre varied greatly but practices regarding infectious risk after monkey bites were generally homogeneous. The risk of Monkey B virus transmission did not readily come to mind in the differential diagnosis of infection risk for many French health professionals.
    Type of Medium: Online Resource
    ISSN: 1863-1959 , 1863-2378
    URL: Issue
    URL: Article
    DOI: 10.1111/zph.v67.2
    DOI: 10.1111/zph.12665
    Language: English
    Publisher: Wiley
    Publication Date: 2020
    detail.hit.zdb_id: 2271118-1
    SSG: 22
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Older adults with SARS‐CoV‐2 infection: Utility of the clinical frailty scale to predict mortality
    Wiley ; 2021
    In:  Journal of Medical Virology Vol. 93, No. 4 ( 2021-04), p. 2453-2460
    Details
    In: Journal of Medical Virology, Wiley, Vol. 93, No. 4 ( 2021-04), p. 2453-2460
    Abstract: Mortality of older patients with COVID‐19 was 30%. The Clinical Frailty Score is a simple tool for assessing COVID19 mortality in older patients. Patients with a score of 1‐4 should be managed regardless of age.
    Type of Medium: Online Resource
    ISSN: 0146-6615 , 1096-9071
    URL: Issue
    URL: Article
    DOI: 10.1002/jmv.v93.4
    DOI: 10.1002/jmv.26766
    RVK:
    XA 10000
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 752392-0
    detail.hit.zdb_id: 1475090-9
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...